Prospective cohort study for genomic evaluation in patients with diffuse large B cell lymphoma after first relapse/progression

Samsung Medical Center0 个研究点目标入组 200 人开始时间: 待定最近更新: 2019年6月17日

试验速览

暂无简介。

•1.Patients with histopathologically confirmed DLBCL
•2.Patients diagnosed with DLBCL who relapsed or were refractory to first-line treatment with rituximab-based immunotherapy
•3.Patients available for genomic analysis of tissues both at diagnosis (paraffin-embedded and stored) and at relapse (paraffin-embedded)
•4.Patients aged =18 years
•5.Patients who provide written informed consent for participation in the prospective cohort study
•6.Patients who provide written informed consent to peripheral blood collection and genetic testing of human tissues

•1.Patients who have no lymphoid malignancy, e.g. myeloid leukemia
•2.Patients with any of the following lymphoid malignancies:
•1)Plasma cell dyscrasia, amyloidosis
•2)Hodgkin lymphoma
•3)Subtypes of B cell non-Hodgkin lymphoma, other than DLBCL
•4)T or NK cell non-Hodgkin lymphoma
•5)Other diseases in the WHO classification of lymphoid malignancies
•3.Patients who have experienced a relapse before
•4.Patients with insufficient or no tissue sample at diagnosis for genomic analysis
•5.Patients who do not understand or provide written informed consent
•6.Patients who do not provide written informed consent to blood collection and genetic testing

发起方